Friday, June 09, 2023
WestVac Biopharma has announced that the Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 vaccine is being approved for Emergency Use Authorisation (EUA) by relevant authorities in China.
Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 vaccine is the first in the world to receive Emergency Use Authorisation (EUA) against XBB descendent lineages of SARS-CoV-2. This vaccine offers a unique option for COVID-19 prevention by providing additional options for prevention and contributing to the ongoing management of the disease.
Coviccine® Trivalent XBB.1.5 is a promising broad-spectrum COVID-19 vaccine that induces a strong immune response, generates high levels of neutralising antibodies, and demonstrates a high protective efficacy against multiple prevalent subvariants.
The subunit vaccine antigen is designed based on the structure of the targeting S-RBD (spike receptor-binding domain) and HR (heptad repeat) proteins of the COVID-19 subvariants XBB.1.5 and BA.5.
Coviccine® Trivalent XBB.1.5 has shown promising results in terms of inducing a high titre of neutralising antibodies against multiple subvariants of the COVID-19 virus, including XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, and BA.2.75. This suggests that the vaccine may provide protection against a broad range of prevalent subvariants, both locally and internationally.